Jaqueline Corrigan-Curay, who serves as acting head of the FDA’s Center for Drug Evaluation and Research, will depart next ...

Illumina expects that adding SomaLogic will aid its “multiomics” business strategy and strengthen the value of its gene ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...

Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...

With backers such as Regeneron’s venture arm, Actio Biosciences is working on medicines that counter a wide range of ...

Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain ...

Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a ...

A new pilot program announced by FDA Commissioner Martin Makary would award vouchers that could cut drug reviews to one or ...